CE-GAN:阿尔茨海默病风险预测的社区进化生成对抗网络
IEEE transactions on medical imaging
|April 8, 2024
概括
这项研究通过检查大脑网络社区的演变,引入了一种新的方法来了解阿尔茨海默病 (AD). 开发的社区进化生成对抗网络 (CE-GAN) 使用成像遗传学数据准确预测AD风险.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 计算生物学 计算生物学
背景情况:
- 目前的阿尔茨海默氏症 (AD) 研究往往忽略了多omics和成像遗传学分析中的大脑网络社区结构.
- 这种忽视可能导致神经退行性疾病发展的不准确模型.
研究的目的:
- 通过脑网络中的社区进化透视来探索阿尔茨海默病 (AD) 发育模式.
- 提出一种新的,可解释的模型来预测AD风险,并提取疾病的病原性.
主要方法:
- 基于信息传播和社区进化,开发了功能性脑退化的数学模型.
- 提出了一个可解释的社区进化生成对抗网络 (CE-GAN),包含社区进化卷曲.
- 使用功能磁共振成像 (fMRI) 和单核酸多态 (SNP) 数据进行实验.
主要成果:
- 在AD风险预测中,CE-GAN获得了91.67%的准确性和91.83%的曲线下面积 (AUC).
- 该模型在相同的数据集上显示出与现有的先进方法相比更高的性能.
- 验证了CE-GAN对病原体提取的有效性.
结论:
- 社区进化是理解阿尔茨海默氏症 (AD) 进展的关键因素.
- CE-GAN提供了一种强大且易于解释的工具,用于使用多模式数据预测AD风险和分析病原性.
- 这种方法通过整合网络社区动态来推进神经成像遗传学.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
830
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
